Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of GM102 alone or with trifluridine/tipiracil in advanced colorectal cancer
2018-000627-13Phase 2Completed
- Sponsor
- GamaMabs Pharma
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of GM-102 in colorectal cancer (CRC) (2 cohorts), sponsored by GamaMabs Pharma. Primary endpoint: Overall tumor response rate. Started Apr 2018; status: completed.
02
Drugs
GM-102
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2018-000627-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000627-13.